Thomas Jefferson University

George Prendergast

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records and Publicatio - Thomas Jefferson University
Address833 Chestnut Street
Philadelphia PA 19023
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R29CA065892     (PRENDERGAST, GEORGE C)Dec 9, 1994 - Nov 30, 1999
    NIH
    FUNCTION OF RHOB PROTEIN
    Role: Principal Investigator
    R01CA082222     (PRENDERGAST, GEORGE C)Sep 30, 1999 - May 31, 2010
    NIH
    Role of RHO in Farnesyltransferase Inhibitor Responses
    Role: Principal Investigator
    R01AG020955     (PRENDERGAST, GEORGE C)Sep 30, 2001 - Aug 31, 2007
    NIH
    Regulation of the MAP Kinase Pathway in Senescence
    Role: Principal Investigator
    R01CA100123     (PRENDERGAST, GEORGE C)May 15, 2003 - Apr 30, 2008
    NIH
    RhoB Signaling in Cancer Suppression and Cell Suicide
    Role: Principal Investigator
    R01CA109542     (PRENDERGAST, GEORGE C)Jul 1, 2004 - Nov 30, 2016
    NIH
    IDO inhibitors for combinatorial cancer therapy
    Role: Principal Investigator
    R21CA159337     (PRENDERGAST, GEORGE C)Sep 26, 2011 - Aug 31, 2014
    NIH
    IDO2 Targeting for pancreatic cancer treatment
    Role: Principal Investigator
    R03CA159315     (PRENDERGAST, GEORGE C)Jul 10, 2012 - Jun 30, 2015
    NIH
    OPPC targeting to improve pancreatic cancer treatment
    Role: Principal Investigator
    R01CA191191     (PRENDERGAST, GEORGE C)Jul 16, 2015 - Jun 30, 2020
    NIH
    IDO2 Targeting in Pancreatic Cancer
    Role: Principal Investigator
    R01DK131173     (PRENDERGAST, GEORGE C)Feb 1, 2022 - Jan 31, 2025
    NIH
    Probing an Unexplored Intracellular Pathway in Diabetes Pathogenesis
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mastrolonardo EV, Nunes KL, Llerena P, Nikitina A, Sobol A, Scott ER, Tuluc M, Davitt CJH, Scher J, Tekumalla S, Mann D, Henao C, Jegede V, Gargano S, Harshyne LA, Alnemri A, Tyshevich A, Kushnarev V, Chasse M, Sookiasian D, Axelrod R, Zhan T, Leiby BE, Old M, Seim N, Mahoney MG, Martinez-Outschoorn U, Cognetti DM, Curry JM, Prendergast GC, Argiris A, South AP, Linnenbach AJ, Johnson JM, Luginbuhl AJ. Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2025 02 03; 31(3):515-528. PMID: 39585339.
      Citations:    
    2. Van NT, Zhang K, Wigmore RM, Kennedy AI, DaSilva CR, Huang J, Ambelil M, Villagomez JH, O'Connor GJ, Longman RS, Cao M, Snook AE, Platten M, Kasenty G, Sigal LJ, Prendergast GC, Kim SV. Dietary L-Tryptophan consumption determines the number of colonic regulatory T cells and susceptibility to colitis via GPR15. Nat Commun. 2023 11 14; 14(1):7363. PMID: 37963876.
      Citations:    
    3. Thomas S, Dilbarov N, Kelly J, Mercogliano G, Prendergast GC. Diet effects on colonic health influence the efficacy of Bin1 mAb immunotherapy for ulcerative colitis. Sci Rep. 2023 07 21; 13(1):11802. PMID: 37479833.
      Citations:    
    4. Thomas S, Prendergast GC. Gut-brain connections in neurodegenerative disease: immunotherapeutic targeting of Bin1 in inflammatory bowel disease and Alzheimer's disease. Front Pharmacol. 2023; 14:1183932. PMID: 37521457.
      Citations:    
    5. Hill BL, Calder AN, Flemming JP, Guo Y, Gilmore SL, Trofa MA, Daniels SK, Nielsen TN, Gleason LK, Antysheva Z, Demina K, Kotlov N, Davitt CJH, Cognetti DM, Prendergast GC, Snook AE, Johnson JM, Kumar G, Linnenbach AJ, Martinez-Outschoorn U, South AP, Curry JM, Harshyne LA, Luginbuhl AJ, Mahoney MG. IL-8 correlates with?nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR-146a mediated mechanism. Mol Carcinog. 2023 09; 62(9):1428-1443. PMID: 37401875.
      Citations:    
    6. Muller AJ, Mondal A, Dey S, Prendergast GC. IDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation. Front Oncol. 2023; 13:1165298. PMID: 37182174.
      Citations:    
    7. Muller AJ, Thomas S, Prendergast GC. A Brief Overview of Cancer Vaccines. Cancer J. 2023 Jan-Feb 01; 29(1):34-37. PMID: 36693156.
      Citations:    
    8. Thomas S, Mercogliano G, Prendergast GC. Bin1 targeted immunotherapy alters the status of the enteric neurons and the microbiome during ulcerative colitis treatment. PLoS One. 2022; 17(11):e0276910. PMID: 36322599.
      Citations:    
    9. Merlo LMF, Peng W, DuHadaway JB, Montgomery JD, Prendergast GC, Muller AJ, Mandik-Nayak L. The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism. J Immunol. 2022 02 01; 208(3):571-581. PMID: 34965962.
      Citations:    
    10. Brochez L, Kruse V, Schadendorf D, Muller AJ, Prendergast GC. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy. Front Immunol. 2021; 12:789473. PMID: 34938297.
      Citations:    
    11. Schultz CW, McCarthy GA, Nerwal T, Nevler A, DuHadaway JB, McCoy MD, Jiang W, Brown SZ, Goetz A, Jain A, Calvert VS, Vishwakarma V, Wang D, Preet R, Cassel J, Summer R, Shaghaghi H, Pommier Y, Baechler SA, Pishvaian MJ, Golan T, Yeo CJ, Petricoin EF, Prendergast GC, Salvino J, Singh PK, Dixon DA, Brody JR. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Mol Cancer Ther. 2021 11; 20(11):2166-2176. PMID: 34413127.
      Citations:    
    12. Dey S, Mondal A, DuHadaway JB, Sutanto-Ward E, Laury-Kleintop LD, Thomas S, Prendergast GC, Mandik-Nayak L, Muller AJ. IDO1 Signaling through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFN?/IL6 Balance to Promote Neovascularization. Cancer Immunol Res. 2021 05; 9(5):514-528. PMID: 33622713.
      Citations:    
    13. Merlo LMF, DuHadaway JB, Montgomery JD, Peng WD, Murray PJ, Prendergast GC, Caton AJ, Muller AJ, Mandik-Nayak L. Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses. Front Immunol. 2020; 11:1861. PMID: 32973768.
      Citations:    
    14. Ladomersky E, Zhai L, Lauing KL, Bell A, Xu J, Kocherginsky M, Zhang B, Wu JD, Podojil JR, Platanias LC, Mochizuki AY, Prins RM, Kumthekar P, Raizer JJ, Dixit K, Lukas RV, Horbinski C, Wei M, Zhou C, Pawelec G, Campisi J, Grohmann U, Prendergast GC, Munn DH, Wainwright DA. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clin Cancer Res. 2020 10 01; 26(19):5232-5245. PMID: 32546647.
      Citations:    
    15. Thomas S, Laury-Kleintop L, Prendergast GC. Reliable detection of indoleamine 2,3 dioxygenase-1 in murine cells and tissues. Methods Enzymol. 2019; 629:219-233. PMID: 31727242.
      Citations:    
    16. Thomas S, Hoxha K, Tran A, Prendergast GC. Bin1 antibody lowers the expression of phosphorylated Tau in Alzheimer's disease. J Cell Biochem. 2019 10; 120(10):18320-18331. PMID: 31211444.
      Citations:    
    17. Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LMF, Pigott E, Keough MP, Rust S, Mellor AL, Mandik-Nayak L, Muller AJ, Prendergast GC. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int Immunol. 2019 03 05; 31(3):181-182. PMID: 31222337.
      Citations:    
    18. Lemos H, Huang L, Prendergast GC, Mellor AL. Immune control by amino acid catabolism during tumorigenesis and?therapy. Nat Rev Cancer. 2019 03; 19(3):162-175. PMID: 30696923.
      Citations:    
    19. Manley K, Bravo-Nuevo A, Minton AR, Sedano S, Marcy A, Reichman M, Tobia A, Artlett CM, Gilmour SK, Laury-Kleintop LD, Prendergast GC. Preclinical study of the long-range safety and anti-inflammatory effects of high-dose oral meglumine. J Cell Biochem. 2019 Jul; 120(7):12051-12062. PMID: 30809852.
      Citations:    
    20. Puligedda RD, Sharma R, Al-Saleem FH, Kouiavskaia D, Velu AB, Kattala CD, Prendergast GC, Lynch DR, Chumakov K, Dessain SK. Capture and display of antibodies secreted by hybridoma cells enables fluorescent on-cell screening. MAbs. 2019 04; 11(3):546-558. PMID: 30794061.
      Citations:    
    21. Almonte-Baldonado R, Bravo-Nuevo A, Gerald D, Benjamin LE, Prendergast GC, Laury-Kleintop LD. RhoB antibody alters retinal vascularization in models of murine retinopathy. J Cell Biochem. 2019 06; 120(6):9381-9391. PMID: 30536763.
      Citations:    
    22. Winters M, DuHadaway JB, Pham KN, Lewis-Ballester A, Badir S, Wai J, Sheikh E, Yeh SR, Prendergast GC, Muller AJ, Malachowski WP. Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase. Eur J Med Chem. 2019 Jan 15; 162:455-464. PMID: 30469041.
      Citations:    
    23. Thomas S, Hoxha K, Alexander W, Gilligan J, Dilbarova R, Whittaker K, Kossenkov A, Prendergast GC, Mullin JM. Intestinal barrier tightening by a cell-penetrating antibody to Bin1, a candidate target for immunotherapy of ulcerative colitis. J Cell Biochem. 2019 03; 120(3):4225-4237. PMID: 30269357.
      Citations:    
    24. Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis M, Villatoro T, Leiby BE, Mandik-Nayak L, Winter JM, Yeo CJ, Prendergast GC, Brody JR. Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers. Clin Cancer Res. 2019 01 15; 25(2):724-734. PMID: 30266763.
      Citations:    
    25. Fox E, Oliver T, Rowe M, Thomas S, Zakharia Y, Gilman PB, Muller AJ, Prendergast GC. Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. Front Oncol. 2018; 8:370. PMID: 30254983.
      Citations:    
    26. Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Semin Immunopathol. 2019 01; 41(1):41-48. PMID: 30203227.
      Citations:    
    27. Nevler A, Muller AJ, Cozzitorto JA, Goetz A, Winter JM, Yeo TP, Lavu H, Yeo CJ, Prendergast GC, Brody JR. A Sub-Type of Familial Pancreatic Cancer:?Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg. 2018 04; 226(4):596-603. PMID: 29426021.
      Citations:    
    28. Jiao X, Velasco-Vel?zquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, Stucky A, Zhang X, Cristofanilli M, Fatatis A, Gray JW, Zhong JF, Prendergast GC, Pestell RG. CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion. Cancer Res. 2018 04 01; 78(7):1657-1671. PMID: 29358169.
      Citations:    
    29. Prendergast GC, Mondal A, Dey S, Laury-Kleintop LD, Muller AJ. Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'. Trends Cancer. 2018 01; 4(1):38-58. PMID: 29413421.
      Citations:    
    30. Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ. Discovery of IDO1 Inhibitors: From Bench to Bedside. Cancer Res. 2017 12 15; 77(24):6795-6811. PMID: 29247038.
      Citations:    
    31. Jusof FF, Bakmiwewa SM, Weiser S, Too LK, Metz R, Prendergast GC, Fraser ST, Hunt NH, Ball HJ. Investigation of the Tissue Distribution and Physiological Roles of Indoleamine 2,3-Dioxygenase-2. Int J Tryptophan Res. 2017; 10:1178646917735098. PMID: 29051706.
      Citations:    
    32. Prendergast GC, Malachowski WJ, Mondal A, Scherle P, Muller AJ. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. Int Rev Cell Mol Biol. 2018; 336:175-203. PMID: 29413890.
      Citations:    
    33. Mandik-Nayak L, DuHadaway JB, Mulgrew J, Pigott E, Manley K, Sedano S, Prendergast GC, Laury-Kleintop LD. RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus. Dis Model Mech. 2017 11 01; 10(11):1313-1322. PMID: 28882929.
      Citations:    
    34. Thomas S, Izard J, Walsh E, Batich K, Chongsathidkiet P, Clarke G, Sela DA, Muller AJ, Mullin JM, Albert K, Gilligan JP, DiGuilio K, Dilbarova R, Alexander W, Prendergast GC. The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. Cancer Res. 2017 04 15; 77(8):1783-1812. PMID: 28292977.
      Citations:    
    35. Merlo LMF, Grabler S, DuHadaway JB, Pigott E, Manley K, Prendergast GC, Laury-Kleintop LD, Mandik-Nayak L. Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis. Clin Immunol. 2017 06; 179:8-16. PMID: 28223071.
      Citations:    
    36. Caux C, Ramos RN, Prendergast GC, Bendriss-Vermare N, M?n?trier-Caux C. A Milestone Review on How Macrophages Affect Tumor Growth. Cancer Res. 2016 11 15; 76(22):6439-6442. PMID: 28148676.
      Citations:    
    37. Mondal A, Smith C, DuHadaway JB, Sutanto-Ward E, Prendergast GC, Bravo-Nuevo A, Muller AJ. IDO1 is an Integral Mediator of Inflammatory Neovascularization. EBioMedicine. 2016 Dec; 14:74-82. PMID: 27889479.
      Citations:    
    38. Kutner T, Kunkel E, Wang Y, George K, Zeger EL, Ali ZA, Prendergast GC, Gilman PB, Wallon UM. Preliminary evaluation of a predictive blood assay to identify patients at high risk of chemotherapy-induced nausea. Support Care Cancer. 2017 02; 25(2):581-587. PMID: 27734152.
      Citations:    
    39. Miyagawa T, Ebinuma I, Morohashi Y, Hori Y, Young Chang M, Hattori H, Maehara T, Yokoshima S, Fukuyama T, Tsuji S, Iwatsubo T, Prendergast GC, Tomita T. BIN1 regulates BACE1 intracellular trafficking and amyloid-? production. Hum Mol Genet. 2016 07 15; 25(14):2948-2958. PMID: 27179792.
      Citations:    
    40. Merlo LM, DuHadaway JB, Grabler S, Prendergast GC, Muller AJ, Mandik-Nayak L. IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism. J Immunol. 2016 06 01; 196(11):4487-97. PMID: 27183624.
      Citations:    
    41. DuHadaway J, Prendergast GC. Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancer. Oncotarget. 2016 Feb 16; 7(7):7372-80. PMID: 26840263.
      Citations:    
    42. Messerschmidt JL, Prendergast GC, Messerschmidt GL. How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. Oncologist. 2016 Feb; 21(2):233-43. PMID: 26834161.
      Citations:    
    43. Thomas S, Prendergast GC. Cancer Vaccines: A Brief Overview. Methods Mol Biol. 2016; 1403:755-61. PMID: 27076165.
      Citations:    
    44. Prendergast GC. Cancer Research: 75th Anniversary of the Field's Most Highly Cited Basic Science Journal. Cancer Res. 2016 Jan 01; 76(1):3. PMID: 26729787.
      Citations:    
    45. Malachowski WP, Winters M, DuHadaway JB, Lewis-Ballester A, Badir S, Wai J, Rahman M, Sheikh E, LaLonde JM, Yeh SR, Prendergast GC, Muller AJ. O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. Eur J Med Chem. 2016 Jan 27; 108:564-576. PMID: 26717206.
      Citations:    
    46. Bravo-Nuevo A, Brandli AA, Gerhart J, Nichols J, Pitts M, Sutera CK, Assali S, Scheinfeld V, Prendergast GC, Stone J, George-Weinstein M. Neuroprotective effect of Myo/Nog cells in the stressed retina. Exp Eye Res. 2016 05; 146:22-25. PMID: 26688580.
      Citations:    
    47. Laury-Kleintop LD, Mulgrew JR, Heletz I, Nedelcoviciu RA, Chang MY, Harris DM, Koch WJ, Schneider MD, Muller AJ, Prendergast GC. Cardiac-specific disruption of Bin1 in mice enables a model of stress- and age-associated dilated cardiomyopathy. J Cell Biochem. 2015 Nov; 116(11):2541-51. PMID: 25939245.
      Citations:    
    48. Thomas S, Mercado JM, DuHadaway J, DiGuilio K, Mullin JM, Prendergast GC. Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function. Dig Dis Sci. 2016 Feb; 61(2):423-32. PMID: 26195312.
      Citations:    
    49. Puccetti P, Fallarino F, Italiano A, Soubeyran I, MacGrogan G, Debled M, Velasco V, Bodet D, Eimer S, Veldhoen M, Prendergast GC, Platten M, Bessede A, Guillemin GJ. Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. PLoS One. 2015; 10(4):e0122046. PMID: 25881064.
      Citations:    
    50. Prendergast GC. A perspective on cancer as an abortive autoimmune response to altered-self. Cancer Res. 2015 Jan 01; 75(1):3-4. PMID: 25559989.
      Citations:    
    51. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqu? A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fuc?kov? J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, J?ger D, Kalinski P, K?rre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Saut?s-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Classification of current anticancer immunotherapies. Oncotarget. 2014 Dec 30; 5(24):12472-508. PMID: 25537519.
      Citations:    
    52. Prendergast GC, Metz R, Muller AJ, Merlo LM, Mandik-Nayak L. IDO2 in Immunomodulation and Autoimmune Disease. Front Immunol. 2014; 5:585. PMID: 25477879.
      Citations:    
    53. Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, Bicciato S, Mazza EM, Macchiarulo A, Vacca C, Iannitti R, Tissi L, Volpi C, Belladonna ML, Orabona C, Bianchi R, Lanz TV, Platten M, Della Fazia MA, Piobbico D, Zelante T, Funakoshi H, Nakamura T, Gilot D, Denison MS, Guillemin GJ, DuHadaway JB, Prendergast GC, Metz R, Geffard M, Boon L, Pirro M, Iorio A, Veyret B, Romani L, Grohmann U, Fallarino F, Puccetti P. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature. 2014 Jul 10; 511(7508):184-90. PMID: 24930766.
      Citations:    
    54. Pigott E, DuHadaway JB, Muller AJ, Gilmour S, Prendergast GC, Mandik-Nayak L. 1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity. 2014 Sep; 47(6):409-18. PMID: 24798341.
      Citations:    
    55. Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother. 2014 Jul; 63(7):721-35. PMID: 24711084.
      Citations:    
    56. Bravo-Nuevo A, Marcy A, Huang M, Kappler F, Mulgrew J, Laury-Kleintop L, Reichman M, Tobia A, Prendergast GC. Meglumine exerts protective effects against features of metabolic syndrome and type II diabetes. PLoS One. 2014; 9(2):e90031. PMID: 24587200.
      Citations:    
    57. Thomas S, DuHadaway J, Prendergast GC, Laury-Kleintop L. Specific in situ detection of murine indoleamine 2, 3-dioxygenase. J Cell Biochem. 2014 Feb; 115(2):391-6. PMID: 24123235.
      Citations:    
    58. Merlo LMF, Pigott E, DuHadaway JB, Grabler S, Metz R, Prendergast GC, Mandik-Nayak L. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J Immunol. 2014 Mar 01; 192(5):2082-2090. PMID: 24489090.
      Citations:    
    59. Metz R, Smith C, DuHadaway JB, Chandler P, Baban B, Merlo LM, Pigott E, Keough MP, Rust S, Mellor AL, Mandik-Nayak L, Muller AJ, Prendergast GC. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int Immunol. 2014 Jul; 26(7):357-67. PMID: 24402311.
      Citations:    
    60. Trabanelli S, Ocadl?kov? D, Ciciarello M, Salvestrini V, Lecciso M, Jandus C, Metz R, Evangelisti C, Laury-Kleintop L, Romero P, Prendergast GC, Curti A, Lemoli RM. The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol. 2014 Feb 01; 192(3):1231-40. PMID: 24391212.
      Citations:    
    61. Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, Foti M, Jemal A, Lawrence TS, Li CI, Mardis ER, Neumann PJ, Pardoll DM, Prendergast GC, Reed JC, Weiner GJ. AACR Cancer Progress Report 2013. Clin Cancer Res. 2013 Oct 15; 19(20 Suppl):S4-98. PMID: 24045178.
      Citations:    
    62. Eldredge HB, Denittis A, Duhadaway JB, Chernick M, Metz R, Prendergast GC. CONCURRENT WHOLE BRAIN RADIOTHERAPY AND SHORT-COURSE CHLOROQUINE IN PATIENTS WITH BRAIN METASTASES: A PILOT TRIAL. J Radiat Oncol. 2013 Sep 01; 2(3). PMID: 24187608.
      Citations:    
    63. Simionescu-Bankston A, Leoni G, Wang Y, Pham PP, Ramalingam A, DuHadaway JB, Faundez V, Nusrat A, Prendergast GC, Pavlath GK. The N-BAR domain protein, Bin3, regulates Rac1- and Cdc42-dependent processes in myogenesis. Dev Biol. 2013 Oct 01; 382(1):160-71. PMID: 23872330.
      Citations:    
    64. Gerald D, Adini I, Shechter S, Perruzzi C, Varnau J, Hopkins B, Kazerounian S, Kurschat P, Blachon S, Khedkar S, Bagchi M, Sherris D, Prendergast GC, Klagsbrun M, Stuhlmann H, Rigby AC, Nagy JA, Benjamin LE. RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription. Nat Commun. 2013; 4:2824. PMID: 24280686.
      Citations:    
    65. Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ, Prendergast GC. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012 Dec 01; 1(9):1460-1468. PMID: 23264892.
      Citations:    
    66. Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB, Goossens V, Roelandt R, Van Hauwermeiren F, Libert C, Declercq W, Callewaert N, Prendergast GC, Degterev A, Yuan J, Vandenabeele P. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 2012 Nov 29; 3:e437. PMID: 23190609.
      Citations:    
    67. Janson C, Kasahara N, Prendergast GC, Colicelli J. RIN3 is a negative regulator of mast cell responses to SCF. PLoS One. 2012; 7(11):e49615. PMID: 23185384.
      Citations:    
    68. Kazerounian S, Gerald D, Huang M, Chin YR, Udayakumar D, Zheng N, O'Donnell RK, Perruzzi C, Mangiante L, Pourat J, Phung TL, Bravo-Nuevo A, Shechter S, McNamara S, Duhadaway JB, Kocher ON, Brown LF, Toker A, Prendergast GC, Benjamin LE. RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. Cancer Res. 2013 Jan 01; 73(1):50-61. PMID: 23135917.
      Citations:    
    69. Prendergast GC. Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future. Oncoimmunology. 2012 Sep 01; 1(6):793-797. PMID: 23162746.
      Citations:    
    70. McGaha TL, Huang L, Lemos H, Metz R, Mautino M, Prendergast GC, Mellor AL. Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev. 2012 Sep; 249(1):135-57. PMID: 22889220.
      Citations:    
    71. Prendergast GC, Metz R. A perspective on new immune adjuvant principles: Reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies. Oncoimmunology. 2012 Sep 01; 1(6):924-929. PMID: 23162760.
      Citations:    
    72. Li J, Ward KM, Zhang D, Dayanandam E, Denittis AS, Prendergast GC, Ayene IS. A bioactive probe of the oxidative pentose phosphate cycle: novel strategy to reverse radioresistance in glucose deprived human colon cancer cells. Toxicol In Vitro. 2013 Feb; 27(1):367-77. PMID: 22926048.
      Citations:    
    73. Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2012 Aug; 2(8):722-35. PMID: 22822050.
      Citations:    
    74. Wojciak-Stothard B, Zhao L, Oliver E, Dubois O, Wu Y, Kardassis D, Vasilaki E, Huang M, Mitchell JA, Harrington LS, Louise H, Prendergast GC, Wilkins MR. Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res. 2012 May 25; 110(11):1423-34. PMID: 22539766.
      Citations:    
    75. Chang MY, Boulden J, Valenzano MC, Soler AP, Muller AJ, Mullin JM, Prendergast GC. Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci. 2012 Jul; 57(7):1813-21. PMID: 22526583.
      Citations:    
    76. Li J, Zhang D, Ward KM, Prendergast GC, Ayene IS. Hydroxyethyl disulfide as an efficient metabolic assay for cell viability in vitro. Toxicol In Vitro. 2012 Jun; 26(4):603-12. PMID: 22321380.
      Citations:    
    77. Chang MY, Smith C, DuHadaway JB, Pyle JR, Boulden J, Soler AP, Muller AJ, Laury-Kleintop LD, Prendergast GC. Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther. 2011 Dec 15; 12(12):1050-8. PMID: 22157149.
      Citations:    
    78. Barberan S, McNair K, Iqbal K, Smith NC, Prendergast GC, Stone TW, Cobb SR, Morris BJ. Altered apoptotic responses in neurons lacking RhoB GTPase. Eur J Neurosci. 2011 Dec; 34(11):1737-46. PMID: 22098422.
      Citations:    
    79. Ha NH, Nair VS, Reddy DN, Mudvari P, Ohshiro K, Ghanta KS, Pakala SB, Li DQ, Costa L, Lipton A, Badwe RA, Fuqua S, Wallon M, Prendergast GC, Kumar R. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res. 2011 Dec 01; 71(23):7259-69. PMID: 22006997.
      Citations:    
    80. Prendergast GC. Cancer: Why tumours eat tryptophan. Nature. 2011 Oct 12; 478(7368):192-4. PMID: 21993754.
      Citations:    
    81. Divanovic S, Sawtell NM, Trompette A, Warning JI, Dias A, Cooper AM, Yap GS, Arditi M, Shimada K, Duhadaway JB, Prendergast GC, Basaraba RJ, Mellor AL, Munn DH, Aliberti J, Karp CL. Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis. 2012 Jan 01; 205(1):152-61. PMID: 21990421.
      Citations:    
    82. Huang M, Satchell L, Duhadaway JB, Prendergast GC, Laury-Kleintop LD. RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. J Cell Biochem. 2011 Jun; 112(6):1572-84. PMID: 21344485.
      Citations:    
    83. Zhang C, Elkahloun AG, Liao H, Delaney S, Saber B, Morrow B, Prendergast GC, Hollander MC, Gills JJ, Dennis PA. Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. Mol Cancer Ther. 2011 Jul; 10(7):1137-48. PMID: 21551261.
      Citations:    
    84. Prendergast GC. Perspectives on emerging trends in cancer research. Cancer Res. 2011 Mar 15; 71(6):2027-8. PMID: 21406392.
      Citations:    
    85. Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem. 2011; 18(15):2257-62. PMID: 21517753.
      Citations:    
    86. Bravo-Nuevo A, Sugimoto H, Iyer S, Fallon Z, Lucas JM, Kazerounian S, Prendergast GC, Kalluri R, Shapiro NI, Benjamin LE. RhoB loss prevents streptozotocin-induced diabetes and ameliorates diabetic complications in mice. Am J Pathol. 2011 Jan; 178(1):245-52. PMID: 21224061.
      Citations:    
    87. Tian L, Huang K, DuHadaway JB, Prendergast GC, Stambolian D. Genomic profiling of miRNAs in two human lens cell lines. Curr Eye Res. 2010 Sep; 35(9):812-8. PMID: 20795863.
      Citations:    
    88. Donover PS, Wojciechowski BS, Thirumaran R, Zemba-Palko V, Prendergast GC, Wallon UM. Development of a monoclonal antibody that specifically detects tissue inhibitor of metalloproteinase-4 (TIMP-4) in formalin-fixed, paraffin-embedded human tissues. J Cell Biochem. 2010 Aug 01; 110(5):1255-61. PMID: 20564221.
      Citations:    
    89. Muller AJ, DuHadaway JB, Chang MY, Ramalingam A, Sutanto-Ward E, Boulden J, Soler AP, Mandik-Nayak L, Gilmour SK, Prendergast GC. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother. 2010 Nov; 59(11):1655-63. PMID: 20640572.
      Citations:    
    90. Metz R, Duhadaway JB, Rust S, Munn DH, Muller AJ, Mautino M, Prendergast GC. Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol Cancer Ther. 2010 Jun; 9(6):1864-71. PMID: 20530717.
      Citations:    
    91. Muller AJ, Mandik-Nayak L, Prendergast GC. Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy. 2010 May; 2(3):293-7. PMID: 20635895.
      Citations:    
    92. Prendergast GC, Metz R, Muller AJ. Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol. 2010 May; 176(5):2082-7. PMID: 20228228.
      Citations:    
    93. McNair K, Spike R, Guilding C, Prendergast GC, Stone TW, Cobb SR, Morris BJ. A role for RhoB in synaptic plasticity and the regulation of neuronal morphology. J Neurosci. 2010 Mar 03; 30(9):3508-17. PMID: 20203211.
      Citations:    
    94. Ciorba MA, Bettonville EE, McDonald KG, Metz R, Prendergast GC, Newberry RD, Stenson WF. Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol. 2010 Apr 01; 184(7):3907-16. PMID: 20181893.
      Citations:    
    95. Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC. Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res. 2010 Mar 01; 70(5):1845-53. PMID: 20160032.
      Citations:    
    96. Prendergast GC. In their own words: interviews with Cell Cycle. Cell Cycle. 2010 Jan 15; 9(2):233-4. PMID: 20081353.
      Citations:    
    97. DeWard AD, Leali K, West RA, Prendergast GC, Alberts AS. Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice. PLoS One. 2009 Sep 21; 4(9):e7102. PMID: 19768111.
      Citations:    
    98. Liss M, Sreedhar N, Keshgegian A, Sauter G, Chernick MR, Prendergast GC, Wallon UM. Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course. Am J Pathol. 2009 Sep; 175(3):940-6. PMID: 19700750.
      Citations:    
    99. Prendergast GC, Metz R, Muller AJ. IDO recruits Tregs in melanoma. Cell Cycle. 2009 Jun 15; 8(12):1818-9. PMID: 19471123.
      Citations:    
    100. Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ, Mandik-Nayak L. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol. 2009 Jun 15; 182(12):7509-17. PMID: 19494274.
      Citations:    
    101. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg. 2009 May; 208(5):781-7; discussion 787-9. PMID: 19476837.
      Citations:    
    102. Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A. 2008 Nov 04; 105(44):17073-8. PMID: 18952840.
      Citations:    
    103. Sebire NJ, Fisher RA, Williams S, Prendergast G, Savage P, Seckl M. Indoleamine 2,3-dioxygenase expression in gestational trophoblastic disease: implications for development of immunotherapeutic approaches. J Reprod Med. 2008 Oct; 53(10):789-92. PMID: 19004406.
      Citations:    
    104. Chien J, Narita K, Rattan R, Giri S, Shridhar R, Staub J, Beleford D, Lai J, Roberts LR, Molina J, Kaufmann SH, Prendergast GC, Shridhar V. A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation. Oncogene. 2008 Dec 11; 27(58):7223-34. PMID: 18806825.
      Citations:    
    105. Prendergast GC, Muller AJ, Ramalingam A, Chang MY. BAR the door: cancer suppression by amphiphysin-like genes. Biochim Biophys Acta. 2009 Jan; 1795(1):25-36. PMID: 18930786.
      Citations:    
    106. Kumar S, Jaller D, Patel B, LaLonde JM, DuHadaway JB, Malachowski WP, Prendergast GC, Muller AJ. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem. 2008 Aug 28; 51(16):4968-77. PMID: 18665584.
      Citations:    
    107. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008 Apr; 222:206-21. PMID: 18364004.
      Citations:    
    108. Ramalingam A, Duhadaway JB, Sutanto-Ward E, Wang Y, Dinchuk J, Huang M, Donover PS, Boulden J, McNally LM, Soler AP, Muller AJ, Duncan MK, Prendergast GC. Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging. Cancer Res. 2008 Mar 15; 68(6):1683-90. PMID: 18339847.
      Citations:    
    109. Kumar S, Malachowski WP, DuHadaway JB, LaLonde JM, Carroll PJ, Jaller D, Metz R, Prendergast GC, Muller AJ. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27; 51(6):1706-18. PMID: 18318466.
      Citations:    
    110. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene. 2008 Jun 26; 27(28):3889-900. PMID: 18317452.
      Citations:    
    111. McDonnell TJ, Chari NS, Cho-Vega JH, Troncoso P, Wang X, Bueso-Ramos CE, Coombes K, Brisbay S, Lopez R, Prendergast G, Logothetis C, Do KA. Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. BMC Med Genomics. 2008 Jan 31; 1:1. PMID: 18237448.
      Citations:    
    112. Li Z, Wang C, Jiao X, Katiyar S, Casimiro MC, Prendergast GC, Powell MJ, Pestell RG. Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. J Biol Chem. 2008 Mar 14; 283(11):7007-15. PMID: 18180298.
      Citations:    
    113. Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene. 2008 May 01; 27(20):2851-7. PMID: 18026137.
      Citations:    
    114. Huang M, Duhadaway JB, Prendergast GC, Laury-Kleintop LD. RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2007 Dec; 27(12):2597-605. PMID: 17951322.
      Citations:    
    115. Chang MY, Boulden J, Katz JB, Wang L, Meyer TJ, Soler AP, Muller AJ, Prendergast GC. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res. 2007 Aug 15; 67(16):7605-12. PMID: 17699764.
      Citations:    
    116. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007 Aug 01; 67(15):7082-7. PMID: 17671174.
      Citations:    
    117. Kamasani U, Duhadaway JB, Alberts AS, Prendergast GC. mDia function is critical for the cell suicide program triggered by farnesyl transferase inhibition. Cancer Biol Ther. 2007 Sep; 6(9):1422-7. PMID: 17786040.
      Citations:    
    118. Ramalingam A, Farmer GE, Stamato TD, Prendergast GC. Bin1 interacts with and restrains the DNA end-binding protein complex Ku. Cell Cycle. 2007 Aug 01; 6(15):1914-8. PMID: 17671430.
      Citations:    
    119. Ramalingam A, Prendergast GC. Bin1 homolog hob1 supports a Rad6-Set1 pathway of transcriptional repression in fission yeast. Cell Cycle. 2007 Jul 01; 6(13):1655-62. PMID: 17611416.
      Citations:    
    120. Prendergast GC, Jaffee EM. Cancer immunologists and cancer biologists: why we didn't talk then but need to now. Cancer Res. 2007 Apr 15; 67(8):3500-4. PMID: 17413003.
      Citations:    
    121. Ghaneie A, Zemba-Palko V, Itoh H, Itoh K, Sakamuro D, Nakamura S, Soler AP, Prendergast GC. Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival. Cancer Biol Ther. 2007 Feb; 6(2):192-4. PMID: 17218774.
      Citations:    
    122. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets. 2007 Feb; 7(1):31-40. PMID: 17305476.
      Citations:    
    123. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007 Jan 15; 67(2):792-801. PMID: 17234791.
      Citations:    
    124. Chang MY, Boulden J, Sutanto-Ward E, Duhadaway JB, Soler AP, Muller AJ, Prendergast GC. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res. 2007 Jan 01; 67(1):100-7. PMID: 17210688.
      Citations:    
    125. Casal E, Federici L, Zhang W, Fernandez-Recio J, Priego EM, Miguel RN, DuHadaway JB, Prendergast GC, Luisi BF, Laue ED. The crystal structure of the BAR domain from human Bin1/amphiphysin II and its implications for molecular recognition. Biochemistry. 2006 Oct 31; 45(43):12917-28. PMID: 17059209.
      Citations:    
    126. Li Z, Wang C, Prendergast GC, Pestell RG. Cyclin D1 functions in cell migration. Cell Cycle. 2006 Nov 01; 5(21):2440-2. PMID: 17106256.
      Citations:    
    127. Huang M, Kamasani U, Prendergast GC. RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3. Oncogene. 2006 Mar 02; 25(9):1281-9. PMID: 16247449.
      Citations:    
    128. Huang M, Prendergast GC. RhoB in cancer suppression. Histol Histopathol. 2006 02; 21(2):213-8. PMID: 16329046.
      Citations:    
    129. Gaspari P, Banerjee T, Malachowski WP, Muller AJ, Prendergast GC, DuHadaway J, Bennett S, Donovan AM. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2006 Jan 26; 49(2):684-92. PMID: 16420054.
      Citations:    
    130. Masumi A, Aizaki H, Suzuki T, DuHadaway JB, Prendergast GC, Komuro K, Fukazawa H. Reduction of hepatitis C virus NS5A phosphorylation through its interaction with amphiphysin II. Biochem Biophys Res Commun. 2005 Oct 21; 336(2):572-8. PMID: 16139795.
      Citations:    
    131. Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res. 2005 Sep 15; 65(18):8065-8. PMID: 16166276.
      Citations:    
    132. Prendergast GC. Chasing cancer: from genes to drugs. Cancer Biol Ther. 2005 Aug; 4(8):901-5. PMID: 16177560.
      Citations:    
    133. Muller AJ, Malachowski WP, Prendergast GC. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets. 2005 Aug; 9(4):831-49. PMID: 16083346.
      Citations:    
    134. Kamasani U, Prendergast GC. Genetic response to DNA damage: proapoptotic targets of RhoB include modules for p53 response and susceptibility to Alzheimer's disease. Cancer Biol Ther. 2005 Mar; 4(3):282-8. PMID: 15876868.
      Citations:    
    135. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005 Mar; 11(3):312-9. PMID: 15711557.
      Citations:    
    136. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, Gandy S. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med. 2005 Jan; 2(1):e18. PMID: 15647781.
      Citations:    
    137. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biol Ther. 2004 Dec; 3(12):1236-42. PMID: 15611650.
      Citations:    
    138. Sandilands E, Cans C, Fincham VJ, Brunton VG, Mellor H, Prendergast GC, Norman JC, Superti-Furga G, Frame MC. RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev Cell. 2004 Dec; 7(6):855-69. PMID: 15572128.
      Citations:    
    139. Kamasani U, Huang M, Duhadaway JB, Prochownik EV, Donover PS, Prendergast GC. Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition. Cancer Res. 2004 Nov 15; 64(22):8389-96. PMID: 15548709.
      Citations:    
    140. Adini I, Rabinovitz I, Sun JF, Prendergast GC, Benjamin LE. RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev. 2003 Nov 01; 17(21):2721-32. PMID: 14597666.
      Citations:    
    141. Prendergast GC. Signal transduction: putting translation before transcription. Cancer Cell. 2003 Oct; 4(4):244-5. PMID: 14585349.
      Citations:    
    142. Tajiri T, Liu X, Thompson PM, Tanaka S, Suita S, Zhao H, Maris JM, Prendergast GC, Hogarty MD. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res. 2003 Aug 15; 9(9):3345-55. PMID: 12960121.
      Citations:    
    143. DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene. 2003 Jun 05; 22(23):3578-88. PMID: 12789266.
      Citations:    
    144. Muller AJ, Baker JF, DuHadaway JB, Ge K, Farmer G, Donover PS, Meade R, Reid C, Grzanna R, Roach AH, Shah N, Soler AP, Prendergast GC. Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Mol Cell Biol. 2003 Jun; 23(12):4295-306. PMID: 12773571.
      Citations:    
    145. Kamasani U, Liu AX, Prendergast GC. Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol Ther. 2003 May-Jun; 2(3):273-80. PMID: 12878865.
      Citations:    
    146. Zeng PY, Rane N, Du W, Chintapalli J, Prendergast GC. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene. 2003 Feb 27; 22(8):1124-34. PMID: 12606940.
      Citations:    
    147. DuHadaway JB, Lynch FJ, Brisbay S, Bueso-Ramos C, Troncoso P, McDonnell T, Prendergast GC. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem. 2003 Feb 15; 88(3):635-42. PMID: 12532338.
      Citations:    
    148. Routhier EL, Donover PS, Prendergast GC. hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress. Oncogene. 2003 Feb 06; 22(5):637-48. PMID: 12569356.
      Citations:    
    149. van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther. 2002 Jun; 1(8):575-83. PMID: 12479217.
      Citations:    
    150. Prendergast GC. CHK and MEK inhibitors team up to trigger cancer cell suicide. Cancer Biol Ther. 2002 May-Jun; 1(3):254-5. PMID: 12432272.
      Citations:    
    151. Zhang B, Prendergast GC, Fenton RG. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res. 2002 Jan 15; 62(2):450-8. PMID: 11809695.
      Citations:    
    152. Prendergast GC. Farnesyltransferase inhibitors: potential therapeutic for inflammatory breast cancer? Breast Dis. 2002; 15:25-32. PMID: 15687643.
      Citations:    
    153. Prendergast GC, Rane N. Farnesyltransferase inhibitors: mechanism and applications. Expert Opin Investig Drugs. 2001 Dec; 10(12):2105-16. PMID: 11772308.
      Citations:    
    154. Prendergast GC. Actin' up: RhoB in cancer and apoptosis. Nat Rev Cancer. 2001 11; 1(2):162-8. PMID: 11905808.
      Citations:    
    155. Liu AX, Rane N, Liu JP, Prendergast GC. RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol Cell Biol. 2001 Oct; 21(20):6906-12. PMID: 11564874.
      Citations:    
    156. Cerniglia GJ, Bernhard EJ, Prendergast GC. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc Natl Acad Sci U S A. 2001 May 22; 98(11):6192-7. PMID: 11353846.
      Citations:    
    157. DuHadaway JB, Sakamuro D, Ewert DL, Prendergast GC. Bin1 mediates apoptosis by c-Myc in transformed primary cells. Cancer Res. 2001 Apr 01; 61(7):3151-6. PMID: 11306501.
      Citations:    
    158. Routhier EL, Burn TC, Abbaszade I, Summers M, Albright CF, Prendergast GC. Human BIN3 complements the F-actin localization defects caused by loss of Hob3p, the fission yeast homolog of Rvs161p. J Biol Chem. 2001 Jun 15; 276(24):21670-7. PMID: 11274158.
      Citations:    
    159. Prendergast GC. Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology. Histol Histopathol. 2001 01; 16(1):269-75. PMID: 11193202.
      Citations:    
    160. Prendergast GC, Oliff A. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. Semin Cancer Biol. 2000 Dec; 10(6):443-52. PMID: 11170866.
      Citations:    
    161. Prendergast GC. Mode of action of farnesyltransferase inhibitors. Lancet Oncol. 2000 Oct; 1:73. PMID: 11905670.
      Citations:    
    162. Elliott K, Ge K, Du W, Prendergast GC. The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program. Oncogene. 2000 Sep 28; 19(41):4669-84. PMID: 11032017.
      Citations:    
    163. Liu A, Prendergast GC. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors. FEBS Lett. 2000 Sep 22; 481(3):205-8. PMID: 11007964.
      Citations:    
    164. Liu Ax, Du W, Liu JP, Jessell TM, Prendergast GC. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol. 2000 Aug; 20(16):6105-13. PMID: 10913192.
      Citations:    
    165. Ge K, Prendergast GC. Bin2, a functionally nonredundant member of the BAR adaptor gene family. Genomics. 2000 Jul 15; 67(2):210-20. PMID: 10903846.
      Citations:    
    166. Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, Sakamuro D, Nelson P, Malkowicz SB, Tomaszewski J, Prendergast GC. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int J Cancer. 2000 Apr 15; 86(2):155-61. PMID: 10738240.
      Citations:    
    167. Prendergast GC. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol. 2000 Apr; 12(2):166-73. PMID: 10712917.
      Citations:    
    168. Ge K, Duhadaway J, Sakamuro D, Wechsler-Reya R, Reynolds C, Prendergast GC. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int J Cancer. 2000 Feb 01; 85(3):376-83. PMID: 10652430.
      Citations:    
    169. Basu A, Rodeck U, Prendergast GC, Howe CC. Loss of insulin-like growth factor I receptor-dependent expression of p107 and cyclin A in cells that lack the extracellular matrix protein secreted protein acidic and rich in cysteine. Cell Growth Differ. 1999 Nov; 10(11):721-8. PMID: 10593648.
      Citations:    
    170. Du W, Prendergast GC. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res. 1999 Nov 01; 59(21):5492-6. PMID: 10554025.
      Citations:    
    171. Du W, Liu A, Prendergast GC. Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res. 1999 Sep 01; 59(17):4208-12. PMID: 10485456.
      Citations:    
    172. Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci U S A. 1999 Aug 17; 96(17):9689-94. PMID: 10449755.
      Citations:    
    173. Megyeri K, Berencsi K, Halazonetis TD, Prendergast GC, Gri G, Plotkin SA, Rovera G, G?ncz?l E. Involvement of a p53-dependent pathway in rubella virus-induced apoptosis. Virology. 1999 Jun 20; 259(1):74-84. PMID: 10364491.
      Citations:    
    174. Elliott K, Sakamuro D, Basu A, Du W, Wunner W, Staller P, Gaubatz S, Zhang H, Prochownik E, Eilers M, Prendergast GC. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene. 1999 Jun 17; 18(24):3564-73. PMID: 10380878.
      Citations:    
    175. Sakamuro D, Prendergast GC. New Myc-interacting proteins: a second Myc network emerges. Oncogene. 1999 May 13; 18(19):2942-54. PMID: 10378691.
      Citations:    
    176. Prendergast GC. Myc and Myb: are the veils beginning to lift? Oncogene. 1999 May 13; 18(19):2914-5. PMID: 10378687.
      Citations:    
    177. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene. 1999 May 13; 18(19):2967-87. PMID: 10378693.
      Citations:    
    178. Du W, Lebowitz PF, Prendergast GC. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors. Cancer Res. 1999 May 01; 59(9):2059-63. PMID: 10232587.
      Citations:    
    179. Prendergast GC, Du W. Targeting farnesyltransferase: is Ras relevant? Drug Resist Updat. 1999 Apr; 2(2):81-84. PMID: 11504474.
      Citations:    
    180. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol. 1999 Mar; 19(3):1831-40. PMID: 10022870.
      Citations:    
    181. Mao NC, Steingrimsson E, DuHadaway J, Wasserman W, Ruiz JC, Copeland NG, Jenkins NA, Prendergast GC. The murine Bin1 gene functions early in myogenesis and defines a new region of synteny between mouse chromosome 18 and human chromosome 2. Genomics. 1999 Feb 15; 56(1):51-8. PMID: 10036185.
      Citations:    
    182. Duhadaway J, Rowe F, Elliott K, Mao NC, Prendergast GC. Bau, a splice form of Neurabin-I that interacts with the tumor suppressor Bin1, inhibits malignant cell transformation. Cell Adhes Commun. 1999; 7(2):99-110. PMID: 10427963.
      Citations:    
    183. Lebowitz PF, Prendergast GC. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 1998 Sep 17; 17(11 Reviews):1439-45. PMID: 9779989.
      Citations:    
    184. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, Barlev N, Berger SL, Prendergast GC, Rauscher FJ. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 1998 Mar 05; 16(9):1097-112. PMID: 9528852.
      Citations:    
    185. Lebowitz PF, Prendergast GC. Functional interaction between RhoB and the transcription factor DB1. Cell Adhes Commun. 1998; 6(4):277-87. PMID: 9865462.
      Citations:    
    186. Wechsler-Reya RJ, Elliott KJ, Prendergast GC. A role for the putative tumor suppressor Bin1 in muscle cell differentiation. Mol Cell Biol. 1998 Jan; 18(1):566-75. PMID: 9418903.
      Citations:    
    187. Wechsler-Reya R, Sakamuro D, Zhang J, Duhadaway J, Prendergast GC. Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing. J Biol Chem. 1997 Dec 12; 272(50):31453-8. PMID: 9395479.
      Citations:    
    188. Sakamuro D, Sabbatini P, White E, Prendergast GC. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene. 1997 Aug 18; 15(8):887-98. PMID: 9285684.
      Citations:    
    189. Wechsler-Reya R, Elliott K, Herlyn M, Prendergast GC. The putative tumor suppressor BIN1 is a short-lived nuclear phosphoprotein, the localization of which is altered in malignant cells. Cancer Res. 1997 Aug 01; 57(15):3258-63. PMID: 9242458.
      Citations:    
    190. Lebowitz PF, Du W, Prendergast GC. Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription. J Biol Chem. 1997 Jun 27; 272(26):16093-5. PMID: 9195903.
      Citations:    
    191. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem. 1997 Jun 20; 272(25):15591-4. PMID: 9188444.
      Citations:    
    192. Lebowitz PF, Sakamuro D, Prendergast GC. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res. 1997 Feb 15; 57(4):708-13. PMID: 9044849.
      Citations:    
    193. Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet. 1996 Sep; 14(1):69-77. PMID: 8782822.
      Citations:    
    194. Prendergast GC, Davide JP, Lebowitz PF, Wechsler-Reya R, Kohl NE. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res. 1996 Jun 01; 56(11):2626-32. PMID: 8653708.
      Citations:    
    195. Negorev D, Riethman H, Wechsler-Reya R, Sakamuro D, Prendergast GC, Simon D. The Bin1 gene localizes to human chromosome 2q14 by PCR analysis of somatic cell hybrids and fluorescence in situ hybridization. Genomics. 1996 Apr 15; 33(2):329-31. PMID: 8725406.
      Citations:    
    196. Sakamuro D, Eviner V, Elliott KJ, Showe L, White E, Prendergast GC. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene. 1995 Dec 07; 11(11):2411-8. PMID: 8570193.
      Citations:    
    197. Lebowitz PF, Davide JP, Prendergast GC. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol. 1995 Dec; 15(12):6613-22. PMID: 8524226.
      Citations:    
    198. Lin HJ, Eviner V, Prendergast GC, White E. Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest. Mol Cell Biol. 1995 Aug; 15(8):4536-44. PMID: 7623844.
      Citations:    
    199. Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF, Der CJ. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene. 1995 Jun 15; 10(12):2289-96. PMID: 7784077.
      Citations:    
    200. Born TL, Frost JA, Sch?nthal A, Prendergast GC, Feramisco JR. c-Myc cooperates with activated Ras to induce the cdc2 promoter. Mol Cell Biol. 1994 Sep; 14(9):5710-8. PMID: 8065306.
      Citations:    
    201. Li LH, Nerlov C, Prendergast G, MacGregor D, Ziff EB. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J. 1994 Sep 01; 13(17):4070-9. PMID: 8076602.
      Citations:    
    202. Prendergast GC, Davide JP, deSolms SJ, Giuliani EA, Graham SL, Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol. 1994 Jun; 14(6):4193-202. PMID: 8196657.
      Citations:    
    203. Prendergast GC, Gibbs JB. Ras regulatory interactions: novel targets for anti-cancer intervention? Bioessays. 1994 Mar; 16(3):187-91. PMID: 8166672.
      Citations:    
    204. Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest. 1993 Dec; 92(6):2746-55. PMID: 8254028.
      Citations:    
    205. Prendergast GC, Davide JP, Kral A, Diehl R, Gibbs JB, Omer CA, Kohl NE. Negative growth selection against rodent fibroblasts targeted for genetic inhibition of farnesyl transferase. Cell Growth Differ. 1993 Sep; 4(9):707-13. PMID: 8241019.
      Citations:    
    206. Omer CA, Kral AM, Diehl RE, Prendergast GC, Powers S, Allen CM, Gibbs JB, Kohl NE. Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases. Biochemistry. 1993 May 18; 32(19):5167-76. PMID: 8494894.
      Citations:    
    207. Ferr?-D'Amar? AR, Prendergast GC, Ziff EB, Burley SK. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain. Nature. 1993 May 06; 363(6424):38-45. PMID: 8479534.
      Citations:    
    208. Prendergast GC, Gibbs JB. Pathways of Ras function: connections to the actin cytoskeleton. Adv Cancer Res. 1993; 62:19-64. PMID: 8109319.
      Citations:    
    209. Prendergast GC, Hopewell R, Gorham BJ, Ziff EB. Biphasic effect of Max on Myc cotransformation activity and dependence on amino- and carboxy-terminal Max functions. Genes Dev. 1992 Dec; 6(12A):2429-39. PMID: 1459463.
      Citations:    
    210. Prendergast GC, Lawe D, Ziff EB. Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation. Cell. 1991 May 03; 65(3):395-407. PMID: 1840505.
      Citations:    
    211. Prendergast GC, Ziff EB. Mbh 1: a novel gelsolin/severin-related protein which binds actin in vitro and exhibits nuclear localization in vivo. EMBO J. 1991 Apr; 10(4):757-66. PMID: 1849072.
      Citations:    
    212. Prendergast GC, Ziff EB. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science. 1991 Jan 11; 251(4990):186-9. PMID: 1987636.
      Citations:    
    213. Prendergast GC, Diamond LE, Dahl D, Cole MD. The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1. Mol Cell Biol. 1990 Mar; 10(3):1265-9. PMID: 2406566.
      Citations:    
    214. Prendergast GC, Ziff EB. DNA-binding motif. Nature. 1989 Oct 05; 341(6241):392. PMID: 2507924.
      Citations:    
    215. Prendergast GC, Cole MD. Posttranscriptional regulation of cellular gene expression by the c-myc oncogene. Mol Cell Biol. 1989 Jan; 9(1):124-34. PMID: 2467185.
      Citations:    
    Prendergast's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (847)
    Explore
    _
    Co-Authors (38)
    Explore
    _
    Similar People (59)
    Explore
    _
    Same Department Expand Description
    Explore
    _